Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    pipeline-prospector-insert-v1
    X

    Find Drugs for Cardiology/Vascular Diseases in Phase III Clinical Development in CANADA

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type

              Companies

              Resverlogix Corp

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Immuno-Oncology 360

              Participation Not Confirmed

              Update your events

              Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk D...

              Contact the Supplier

              Lead Product(s): Apabetalone

              Therapeutic Area: Cardiology/Vascular Diseases

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 13, 2020

              Details:

              BETonMACEresults show 57% hazard reduction in primary mace for patients on apabetalone and new oral anti-diabetic treatments.

              Acasti Pharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Immuno-Oncology 360

              Participation Not Confirmed

              Update your events

              Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

              Contact the Supplier

              Lead Product(s): Omega-3 phospholipid

              Therapeutic Area: Cardiology/Vascular Diseases

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 13, 2020

              Details:

              A phase 3 trial of Acasti Pharma’s omega-3 drug CaPre has missed its primary endpoint, denting its hopes of challenging Amarin’s Vascepa for the hypertriglyceridemia market.

              PharmaCompass__DigitalAd